Современные достижения в диагностике и лечении рефрактерной формы гастроэзофагеальной рефлюксной болезни
Современные достижения в диагностике и лечении рефрактерной формы гастроэзофагеальной рефлюксной болезни
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель обзора – представить современные данные о причинах, методах диагностики и способах лечения рефрактерной формы гастроэзофагеальной рефлюксной болезни (ГЭРБ).
Рефрактерная ГЭРБ – это сохранение типичных симптомов заболевания и/или неполное заживление слизистой оболочки пищевода на фоне приема стандартной дозы ингибиторов протонной помпы (ИПП) 1 раз в день в течение 8 нед. Причины отсутствия ответа на проводимое лечения делятся на связанные с пациентом, связанные с терапией, а также не имеющие связи с ГЭРБ. Диагностические подходы включают в себя проведение рентгенологического исследования пищевода и желудка, эзофагогастродуоденоскопии с биопсией, 24-часовой рН-импедансометрии, манометрии пищевода. В зависимости от причин отсутствия ответа на проводимую терапию, лечение может включать изменение образа жизни, удвоение дозы ИПП, замену ИПП на другой, добавление Н2-блокаторов гистаминовых рецепторов, прокинетиков, антацидов, альгинатов и адсорбентов. При неэффективности консервативного лечения возможно рассмотрение вопроса об альтернативных методах, таких как хирургическое лечение.
Рефрактерное течение ГЭРБ представляет собой серьезную клиническую проблему. Отсутствие ответа на 8-недельную терапию ИПП требует проведения тщательной дифференциальной диагностики с применением дополнительных методов обследования. Выявление причин рефрактерности к проводимой терапии позволяет оптимизировать подходы к ее преодолению и выбирать оптимальную тактику лечения.
Ключевые слова: гастроэзофагеальная рефлюксная болезнь, рефрактерные симптомы, ингибиторы протонной помпы.
Refractory GERD is the preservation of typical symptoms of the disease and/or incomplete healing of the esophageal mucosa against the background of taking a standard dose of proton pump inhibitors (PPI) once a day for 8 weeks. The reasons for the lack of response to the treatment are divided into related to the patient, related to therapy, and not related to GERD. Diagnostic approaches include x-ray examination of the esophagus and stomach, endoscopy with biopsy, 24-hour Impedance-pH monitoring, esophageal manometry. Depending on the reasons for the lack of response to the therapy, treatment may include lifestyle changes, doubling the dose of PPI, replacing PPI with another, adding H2-receptor antagonists, prokinetics, antacids, alginates and adsorbents. If conservative treatment is ineffective, it is possible to consider alternative methods, such as surgical treatment.
Refractory GERD is a serious clinical problem. The absence of an answer to 8-week therapy with PPI requires a thorough differential diagnosis using additional examination methods. The identification of the causes of refractory to the therapy allows to optimize the approaches to its overcoming and to choose the optimal treatment.
Keywords: gastroesophageal reflux disease, refractory symptoms, proton pump inhibitors.
Рефрактерная ГЭРБ – это сохранение типичных симптомов заболевания и/или неполное заживление слизистой оболочки пищевода на фоне приема стандартной дозы ингибиторов протонной помпы (ИПП) 1 раз в день в течение 8 нед. Причины отсутствия ответа на проводимое лечения делятся на связанные с пациентом, связанные с терапией, а также не имеющие связи с ГЭРБ. Диагностические подходы включают в себя проведение рентгенологического исследования пищевода и желудка, эзофагогастродуоденоскопии с биопсией, 24-часовой рН-импедансометрии, манометрии пищевода. В зависимости от причин отсутствия ответа на проводимую терапию, лечение может включать изменение образа жизни, удвоение дозы ИПП, замену ИПП на другой, добавление Н2-блокаторов гистаминовых рецепторов, прокинетиков, антацидов, альгинатов и адсорбентов. При неэффективности консервативного лечения возможно рассмотрение вопроса об альтернативных методах, таких как хирургическое лечение.
Рефрактерное течение ГЭРБ представляет собой серьезную клиническую проблему. Отсутствие ответа на 8-недельную терапию ИПП требует проведения тщательной дифференциальной диагностики с применением дополнительных методов обследования. Выявление причин рефрактерности к проводимой терапии позволяет оптимизировать подходы к ее преодолению и выбирать оптимальную тактику лечения.
Ключевые слова: гастроэзофагеальная рефлюксная болезнь, рефрактерные симптомы, ингибиторы протонной помпы.
________________________________________________
Refractory GERD is the preservation of typical symptoms of the disease and/or incomplete healing of the esophageal mucosa against the background of taking a standard dose of proton pump inhibitors (PPI) once a day for 8 weeks. The reasons for the lack of response to the treatment are divided into related to the patient, related to therapy, and not related to GERD. Diagnostic approaches include x-ray examination of the esophagus and stomach, endoscopy with biopsy, 24-hour Impedance-pH monitoring, esophageal manometry. Depending on the reasons for the lack of response to the therapy, treatment may include lifestyle changes, doubling the dose of PPI, replacing PPI with another, adding H2-receptor antagonists, prokinetics, antacids, alginates and adsorbents. If conservative treatment is ineffective, it is possible to consider alternative methods, such as surgical treatment.
Refractory GERD is a serious clinical problem. The absence of an answer to 8-week therapy with PPI requires a thorough differential diagnosis using additional examination methods. The identification of the causes of refractory to the therapy allows to optimize the approaches to its overcoming and to choose the optimal treatment.
Keywords: gastroesophageal reflux disease, refractory symptoms, proton pump inhibitors.
Список литературы
1. Ивашкин В.Т., Маев И.В., Трухманов А.С., Баранская Е.К., Дронова О.Б., Зайратьянц О.В., Сайфутдинов Р.Г., Шептулин А.А., Лапина Т.Л., Пирогов С.С., Кучерявый Ю.А., Сторонова О.А., Андреев Д.Н. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(4):75-95 [Ivashkin VT, Maev IV, Trukhmanov AS, Baranskaya EK, Dronova OB, Zayrat’yants OV, Sayfutdinov RG, Sheptulin AA, Lapina TL, Pirogov SS, Kucheryavyy YuA, Storonova OA, Andreev DN. Clinical recommendations of the Russian gastroenterological association for the diagnosis and treatment of gastroesophageal reflux disease. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2017;27(4):75-95 (In Russ.)].
doi: 10.22416/1382-4376-2017-27-4-75-95
2. Трухманов А.С. Диагностика и лечение гастроэзофагеальной рефлюксной болезни. Терапевтический архив. 2011;83(8):44-48 [Trukhmanov AS. Diagnosis and treatment of gastroesophageal reflux disease. Terapevticheskiy Arkhiv. 2011;83(8):44-48 (In Russ.)]
3. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, and the Global Consensus Group. The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. Am J Gastroenterol. 2006;101:1900-1920.
4. El-Serag HB, Ergun GA, Pandolfino J, Fitzgerald S, Tran T, Kramer JR. Obesity increases oesophageal acid exposure. Gut. 2007;56:749-755.
5. Ивашкин В.Т., Маев И.В., Трухманов А.С. Пищевод Баррета. В 2-х т. Москва: Издательство «Шико»; 2011. С. 608-624 [Ivashkin VT,
Maev IV, Trukhmanov AS. Pishchevod Barreta [Barrett’s esophagus]. Moscow: Shiko; 2011. P. 608-624 (In Russ.)].
6. Bytzer P, van Zanten SV, Mattsson H, Wernersson B. Partial symptomresponse to proton pump inhibitors in patients with nonerosive reflux disease or reflux oesophagitis – a post hoc analysis of 5796 patients. Aliment Pharmacol Ther. 2012;36:635-643.
7. Cicala M, Emerenziani S, Guarino MP, Ribolsi M. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World J Gastroenterol. 2013;19(39):6529-6535.
8. Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;23:1473-14777.
9. Johnson DA, Lauritsen K, Junghard O, Levine D. Evaluation of symptoms is an unreliable predictor of relapse of erosive esophagitis in patients receiving maintenance PPI therapy. Gastroenterology. 2003;124(4 Suppl 1):A540.
10. Fass R, Thomas S, Traxler B, Sostek M. Patient reported outcome of heartburn improvement: doubling the proton pump inhibitor (PPI) dose in patient who failed standard dose PPI vs. switching to a different PPI. Gastroenterology. 2004;146:A37.
11. Chey WD, Inadomi JM, Booher AM, Sharma VK, Fendrick AM, Howden CW. Primary-care physicians’ perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol. 2005;100(6):1237-1242.
12. Yasuda S, Ohnishi A, Ogawa T, et al. Pharmacokinetic properties of E3810 a new proton pump ingibitor, in healthy male volunteers. Int J Clin Pharmacol Ther. 1994;32;466-473.
13. Boeckxstaens GE. Alterations confined to the gastro-oesophageal junction: the relationship between low LOSP, TLOSRs, hiatus hernia and acid pocket. Best Pract Res Clin Gastroenterol. 2010;24:821-829.
14. Сhang P, Friedenberg F. Obesity and GERD. Gastroenterol Clin. 2014;43:161-173.
15. Kouklakis G, Moschos J, Kountouras J. Relationship between obesity and gastroesophageal reflux disease as recorded by 3-hour esophageal pH monitoring. Rom J Gastroenterol. 2005;14(2):117-121.
16. El-Serag HB, Ergun GA, Pandolfino J, Fitzgerald S, Tran T, Kramer JR. Obesity increases oesophageal acid exposure. Gut. 2007;56:749-755.
17. Wu JC, Lai LH, Chow DK, Wong GL, Sung JJ, Chan FK. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease. Neurogastroenterol Motil. 2011;23(2):155-160.
18. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2004;5(2):181-202.
19. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79(1):103-113.
20. Furuta T, Sugimoto M, Kodaira C, et al. CYP2C19 genotype is associated with symptomatic recurrence of GORD during maintenance therapy with low-dose lansoprazole. Eur J Clin Pharmacol. 2009;65:693-698.
21. Serrano D, Torrado S, Torrado-Santiago S, Gisbert JP. The influence of CYP2C19 Genetic polymorphism on the Pharmacokinetics/Pharmacodynamics of Proton Pump Inhibitor-Containing Helicobacter pylori treatment. Curr Drug Metab. 2012;13(9):1303-1312.
22. Евсютина Ю.В., Трухманов А.С. Новый взгляд на проблему гастроэзофагеальной рефлюксной болезни, рефрактерной к лечению ингибиторами протонной помпы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;(5):4-9 [Evsyuti-na YuV, Trukhmanov AS. A new look at the problem of gastroesophageal reflux disease, refractory to the treatment with proton pump inhibitors. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2014;(5):4-9 (In Russ.)].
23. Lee YC, Lin JT, Wang HP, et al. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. J Gastroenterol Hepatol. 2007;22(8):1286-1292.
24. Oestreich JH, Best LG, Dobesh PP. Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans. Am Heart J. 2014;167(3):413-418.
25. Isomoto H, Inoue K, Kohno S. Interleukin-8 levels in esophageal mucosa and long-term clinical outcome of patients with reflux esophagitis. Scand J Gastroenterol. 2007;42:410-411.
26. Евсютина Ю.В. Клинико-морфологические характеристики гастроэзофагеальной рефлюксной болезни, рефрактерной к лечению ингибиторами протонной помпы. Автореф. дис. … канд. мед. наук. 14.01.04 – внутренние болезни. Москва; 2015 [Evsyutina YuV. Kliniko-morfologicheskie kharakteristiki gastroezofageal’noy reflyuksnoy bolezni, refrakternoy k lecheniyu ingibitorami protonnoy pompy [Clinico-morphological characteristics of gastroesophageal reflux disease, refractory to treatment with proton pump inhibitors]. Author’s abstract. dis. ... cand. med. sciences. 14.01.04 – internal diseases. Moscow; 2015 (In Russ.)].
27. Mainie I, Tutuian R, Shay S, et al. Acid and nonacid reflux in patients with persistent symptoms despite acid suppressive therapy. A multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006 ;55:1398-1402. doi: 10.1136/gut.2005.087668
28. Kunsch S, Neesse A, Linhart T, Nell C, Gress TM, Ellenrieder V. Prospective evaluation of duodenogastroesophageal reflux in gastro-esophageal reflux disease patients refractory to proton pump inhibitor therapy. Digestion. 2012;86(4):315-322.
29. Tavakkoli A, Sayed BA, Talley NJ, Moshiree B. Acid and non-acid reflux in patients refractory to proton pump inhibitor therapy: is gastroparesis a factor? World J Gastroenterol. 2013;19(37):6193-6198.
30. Kudara N, Chiba T, Orii S, Suzuki K. Gastric emptying of patients with persistent reflux symptoms and erosive esophagitis under PPI therapy. Neurogastroenterol Motil. 2004;16:654.
31. Mirbagheri SA, Sadeghi A, Amouie M, et al. Pyloric injection of botulinum toxin for the treatment of refractory GERD accompanied with gastroparesis: a preliminary report. Dig Dis Sci. 2008;53(10):2621-2626.
32. Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology. 2009;137:588-597.
33. Calatayud S, Garcia-Zaragoza E, Hernandez C, Quintana E, Felipo V, Esplugues JV, et al. Downregulation of nNOS and synthesis of PGs associated with endotoxin-induced delay in gastric emptying. Am J Physiol Gastrointest Liver Physiol. 2002;283:G1360-G1367.
34. Ивашкин В.Т., Трухманов А.С. Эволюция представлений о роли нарушений двигательной функции пищевода в патогенезе гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2010;27(2):13-19 [Ivashkin VT, Trukhmanov AS. Evolution of ideas about the role of disorders of the motor function of the esophagus in the pathogenesis of gastroesophageal reflux disease. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2010;27(2):13-19 (In Russ.)].
35. Маев И.В., Самсонов А.А., Андреев Д.Н. Роль и место антацидов в современных алгоритмах терапии кислотозависимых заболеваний. Фарматека. 2013;(2):66-72 [Maev IV, Samsonov AA, Andreev DN. The role and place of antacids in modern algorithms for the therapy of acid-dependent diseases. Farmateka. 2013;(2):66-72 (In Russ.)].
36. Humphries TJ, Galmiche JP, Avasthy N. Rabeprazole is as effective as omeprazole in normalising esophageal acid exposure. Am J Gastroenterol. 1999;94:A2587. Abstract.
37. Pace F, Pallotta S, Casalini S, Porro GB. A review of rabeprazole in the treatment of acid-related diseases. Ther Clin Risk Manag. 2007 Jun;3(3):363-379.
38. Евсютина Ю.В., Трухманов А.С. Недостаточный ответ на терапию ингибиторами протонного насоса: причины и тактика ведения пациентов. Терапевтический архив. 2015;87(2):85-89 [Evsyutina YuV, Trukhmanov AS. Inadequate response to proton pump inhibitor therapy: causes and tactics of patient management. Terapevticheskiy Arkhiv. 2015;87(2):85-89 (In Russ.)].
39. Пасечников В.Д. Ключи к выбору оптимального ингибитора протонной помпы для терапии кислотозависимых заболеваний. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. Rossiyskiy 2004;(3):32-39 [Pasechnikov VD. Keys to choosing the optimal proton pump inhibitor for the treatment of acid-dependent diseases. Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2004;(3):32-39 (In Russ.)].
40. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003 Jun 15;17(12):1507-1514.
41. Aziz Q, Fass R, Gyawali Prakash C, et al. Esophageal disorders. Gastroenterology. 2016;150:1368-1379.
42. Шептулин А.А., Кайбышева В.О. Функциональная изжога и гиперчувствительность пищевода к рефлюксу (По материалам Римских критериев функциональных заболеваний пищевода IV пересмотра). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(2):13-18 [Sheptulin AA, Kaibysheva VO. Functional heartburn and hypersensitivity of the esophagus to reflux (Based on the Roman criteria for functional diseases of the esophagus IV revision). Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2017;27(2):13-18 (In Russ.)].
43. Mermelstein J, Mermelstein AC, Chait MM. Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. Clin Exper Gastroenterol. 2018;11:119-134.
44. Blaser MJ, Theodore E. Woodward Award: Global Warming and the Human Stomach: Microecology Follows Macroecology. Trans Am Clin Climatol Assoc. 2005;116:65-76.
45. Ahmed N, Sechi LA. Helicobacter pylori and gastroduodenal pathology: New threats of the old friend. Ann Clin Microbiol Antimicrob. 2005;4:1.
46. Nayoung Kim, Lee SW, Kim JI, et al. Effect of Helicobacter pylori Eradication on the Development of Reflux Esophagitis and Gastroesophageal Reflux Symptoms: A Nationwide Multi-Center Prospective Study. Gut Liver. 2011 Dec;5(4):437-446.
47. Диагностика и лечение инфекции Helicobacter pylori – отчет согласительной конференции Маастрихт IV/Флоренция. Вестник практического врача. 2012;Спецвыпуск 1:6-22 [Diagnosis and treatment of Helicobacter pylori infection – report of conciliation conference Maastricht IV / Florence. Vestnik Prakticheskogo Vracha. 2012;Special Issue 1:6-22 (In Russ.)].
48. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease – where next? Aliment Pharmacol Ther. 2005;22(2):79-94.
49. Evsyutina YV, Trukhmanov AS, Ivashkin VT. Family case of achalasia cardia: Case report and review of literature. World J Gastroenterol. 2014;20(4):1114-1118.
50. Boeckxstaens G, El-Serag HB, Smout AJ, Kahrilas PJ. Symptomatic reflux disease: the present, the past and the future. Gut. 2014;63(7):1185-1193.
51. Pohl D, Tutuian R. Reflux monitoring: pH-metry, Bilitec and oesophageal impedance measurements. Best Pract Res Clin Gastroenterol. 2009;23(3):299-331.
52. Mainie I, Tutuian R, Castell DO. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. J Clin Gastroenterol. 2008;42(6):676-679.
53. Rackoff A, Agrawal A, Hila A, Mainie I, Tutuian R, Castell DO. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus. 2005;18(6):370-373.
54. Кайбышева В.О., Трухманов А.С., Ивашкин В.Т. Гастроэзофагеальная рефлюксная болезнь, резистентная к терапии ингибиторами протонной помпы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2011;21(4):4-13 [Kaybysheva VO, Trukhmanov AS, Ivashkin VT. Gastroesophageal reflux disease, resistant to therapy with proton pump inhibitors. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2011;21(4):4-13 (In Russ.)].
55. Ren LH, Chen WX, Qian LJ, Li S, Gu M, Shi RH. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis. World J Gastroenterol. 2014;20(9):2412-2419.
56. Li S, Shi S, Chen F, Lin J. The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trials. Gastroenterol Res Pract. 2014;2014:307805.
57. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem. 1997;272(36):22438-22446.
58. Sarosiek I, Olyaee M, Majewski M, et al. Significant Increase of Esophageal Mucin Secretion in Patients with Reflux Esophagitis After Healing with Rabeprazole: Its Esophagoprotective Potential. Dig Dis Sci. 2009;54:2137-2142.
59. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308.
60. Jafri SM, Arora G, Triadafilopoulos G. What is left of the endoscopic antireflux devices? Curr Opin Gastroenterol. 2009;25:352.
61. Triadafilopoulos G, DiBlaise JK, Nostrant TT, et al. Long-term experience with the Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the US open label trial. Program and abstracts of Digestive Disease Week 2001; May 20-23, 2001; Atlanta, Georgia.
62. Utely DS, Kim MS, Vierra MA, et al. Augmentation of lower esophageal sphincter pressure and gastric yield pressure after radiofrequency energy delivery to the gastroesophageal junction: a porcine model. Gastrointest Endosc. 2000;52:81-86.
63. Mason RJ, Demeester TR, Schurr MO, et al. Per oral endoscopic Nissen fundoplication: the introduction of a new era. Program and abstracts of Digestive Disease Week 2001; May 20-23, 2001; Atlanta, Georgia. [ASGE Abstract #736].
64. Scarpellini E, Ang D, Pauwels A, De Santis A, Vanuytsel T, Tack J. Management of refractory typical GERD symptoms. Nat Rev Gastroenterol Hepatol. 2016;13(5):281-294.
65. Skubleny D, Switzer NJ, Dang J, et al. LINX(®) magnetic esophageal sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: a systematic review and meta-analysis. Surg Endosc. 2017;31(8):3078-3084.
doi: 10.22416/1382-4376-2017-27-4-75-95
2. [Trukhmanov AS. Diagnosis and treatment of gastroesophageal reflux disease. Terapevticheskiy Arkhiv. 2011;83(8):44-48 (In Russ.)]
3. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, and the Global Consensus Group. The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. Am J Gastroenterol. 2006;101:1900-1920.
4. El-Serag HB, Ergun GA, Pandolfino J, Fitzgerald S, Tran T, Kramer JR. Obesity increases oesophageal acid exposure. Gut. 2007;56:749-755.
5. [Ivashkin VT, Maev IV, Trukhmanov AS. Pishchevod Barreta [Barrett’s esophagus]. Moscow: Shiko; 2011. P. 608-624 (In Russ.)].
6. Bytzer P, van Zanten SV, Mattsson H, Wernersson B. Partial symptomresponse to proton pump inhibitors in patients with nonerosive reflux disease or reflux oesophagitis – a post hoc analysis of 5796 patients. Aliment Pharmacol Ther. 2012;36:635-643.
7. Cicala M, Emerenziani S, Guarino MP, Ribolsi M. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World J Gastroenterol. 2013;19(39):6529-6535.
8. Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;23:1473-14777.
9. Johnson DA, Lauritsen K, Junghard O, Levine D. Evaluation of symptoms is an unreliable predictor of relapse of erosive esophagitis in patients receiving maintenance PPI therapy. Gastroenterology. 2003;124(4 Suppl 1):A540.
10. Fass R, Thomas S, Traxler B, Sostek M. Patient reported outcome of heartburn improvement: doubling the proton pump inhibitor (PPI) dose in patient who failed standard dose PPI vs. switching to a different PPI. Gastroenterology. 2004;146:A37.
11. Chey WD, Inadomi JM, Booher AM, Sharma VK, Fendrick AM, Howden CW. Primary-care physicians’ perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol. 2005;100(6):1237-1242.
12. Yasuda S, Ohnishi A, Ogawa T, et al. Pharmacokinetic properties of E3810 a new proton pump ingibitor, in healthy male volunteers. Int J Clin Pharmacol Ther. 1994;32;466-473.
13. Boeckxstaens GE. Alterations confined to the gastro-oesophageal junction: the relationship between low LOSP, TLOSRs, hiatus hernia and acid pocket. Best Pract Res Clin Gastroenterol. 2010;24:821-829.
14. Сhang P, Friedenberg F. Obesity and GERD. Gastroenterol Clin. 2014;43:161-173.
15. Kouklakis G, Moschos J, Kountouras J. Relationship between obesity and gastroesophageal reflux disease as recorded by 3-hour esophageal pH monitoring. Rom J Gastroenterol. 2005;14(2):117-121.
16. El-Serag HB, Ergun GA, Pandolfino J, Fitzgerald S, Tran T, Kramer JR. Obesity increases oesophageal acid exposure. Gut. 2007;56:749-755.
17. Wu JC, Lai LH, Chow DK, Wong GL, Sung JJ, Chan FK. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease. Neurogastroenterol Motil. 2011;23(2):155-160.
18. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2004;5(2):181-202.
19. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79(1):103-113.
20. Furuta T, Sugimoto M, Kodaira C, et al. CYP2C19 genotype is associated with symptomatic recurrence of GORD during maintenance therapy with low-dose lansoprazole. Eur J Clin Pharmacol. 2009;65:693-698.
21. Serrano D, Torrado S, Torrado-Santiago S, Gisbert JP. The influence of CYP2C19 Genetic polymorphism on the Pharmacokinetics/Pharmacodynamics of Proton Pump Inhibitor-Containing Helicobacter pylori treatment. Curr Drug Metab. 2012;13(9):1303-1312.
22. [Evsyuti-na YuV, Trukhmanov AS. A new look at the problem of gastroesophageal reflux disease, refractory to the treatment with proton pump inhibitors. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2014;(5):4-9 (In Russ.)].
23. Lee YC, Lin JT, Wang HP, et al. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. J Gastroenterol Hepatol. 2007;22(8):1286-1292.
24. Oestreich JH, Best LG, Dobesh PP. Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans. Am Heart J. 2014;167(3):413-418.
25. Isomoto H, Inoue K, Kohno S. Interleukin-8 levels in esophageal mucosa and long-term clinical outcome of patients with reflux esophagitis. Scand J Gastroenterol. 2007;42:410-411.
26.[Evsyutina YuV. Kliniko-morfologicheskie kharakteristiki gastroezofageal’noy reflyuksnoy bolezni, refrakternoy k lecheniyu ingibitorami protonnoy pompy [Clinico-morphological characteristics of gastroesophageal reflux disease, refractory to treatment with proton pump inhibitors]. Author’s abstract. dis. ... cand. med. sciences. 14.01.04 – internal diseases. Moscow; 2015 (In Russ.)].
27. Mainie I, Tutuian R, Shay S, et al. Acid and nonacid reflux in patients with persistent symptoms despite acid suppressive therapy. A multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006 ;55:1398-1402. doi: 10.1136/gut.2005.087668
28. Kunsch S, Neesse A, Linhart T, Nell C, Gress TM, Ellenrieder V. Prospective evaluation of duodenogastroesophageal reflux in gastro-esophageal reflux disease patients refractory to proton pump inhibitor therapy. Digestion. 2012;86(4):315-322.
29. Tavakkoli A, Sayed BA, Talley NJ, Moshiree B. Acid and non-acid reflux in patients refractory to proton pump inhibitor therapy: is gastroparesis a factor? World J Gastroenterol. 2013;19(37):6193-6198.
30. Kudara N, Chiba T, Orii S, Suzuki K. Gastric emptying of patients with persistent reflux symptoms and erosive esophagitis under PPI therapy. Neurogastroenterol Motil. 2004;16:654.
31. Mirbagheri SA, Sadeghi A, Amouie M, et al. Pyloric injection of botulinum toxin for the treatment of refractory GERD accompanied with gastroparesis: a preliminary report. Dig Dis Sci. 2008;53(10):2621-2626.
32. Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology. 2009;137:588-597.
33. Calatayud S, Garcia-Zaragoza E, Hernandez C, Quintana E, Felipo V, Esplugues JV, et al. Downregulation of nNOS and synthesis of PGs associated with endotoxin-induced delay in gastric emptying. Am J Physiol Gastrointest Liver Physiol. 2002;283:G1360-G1367.
34. [Ivashkin VT, Trukhmanov AS. Evolution of ideas about the role of disorders of the motor function of the esophagus in the pathogenesis of gastroesophageal reflux disease. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2010;27(2):13-19 (In Russ.)].
35.[Maev IV, Samsonov AA, Andreev DN. The role and place of antacids in modern algorithms for the therapy of acid-dependent diseases. Farmateka. 2013;(2):66-72 (In Russ.)].
36. Humphries TJ, Galmiche JP, Avasthy N. Rabeprazole is as effective as omeprazole in normalising esophageal acid exposure. Am J Gastroenterol. 1999;94:A2587. Abstract.
37. Pace F, Pallotta S, Casalini S, Porro GB. A review of rabeprazole in the treatment of acid-related diseases. Ther Clin Risk Manag. 2007 Jun;3(3):363-379.
38. [Evsyutina YuV, Trukhmanov AS. Inadequate response to proton pump inhibitor therapy: causes and tactics of patient management. Terapevticheskiy Arkhiv. 2015;87(2):85-89 (In Russ.)].
39.[Pasechnikov VD. Keys to choosing the optimal proton pump inhibitor for the treatment of acid-dependent diseases. Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2004;(3):32-39 (In Russ.)].
40. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003 Jun 15;17(12):1507-1514.
41. Aziz Q, Fass R, Gyawali Prakash C, et al. Esophageal disorders. Gastroenterology. 2016;150:1368-1379.
42. [Sheptulin AA, Kaibysheva VO. Functional heartburn and hypersensitivity of the esophagus to reflux (Based on the Roman criteria for functional diseases of the esophagus IV revision). Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2017;27(2):13-18 (In Russ.)].
43. Mermelstein J, Mermelstein AC, Chait MM. Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. Clin Exper Gastroenterol. 2018;11:119-134.
44. Blaser MJ, Theodore E. Woodward Award: Global Warming and the Human Stomach: Microecology Follows Macroecology. Trans Am Clin Climatol Assoc. 2005;116:65-76.
45. Ahmed N, Sechi LA. Helicobacter pylori and gastroduodenal pathology: New threats of the old friend. Ann Clin Microbiol Antimicrob. 2005;4:1.
46. Nayoung Kim, Lee SW, Kim JI, et al. Effect of Helicobacter pylori Eradication on the Development of Reflux Esophagitis and Gastroesophageal Reflux Symptoms: A Nationwide Multi-Center Prospective Study. Gut Liver. 2011 Dec;5(4):437-446.
47. [Diagnosis and treatment of Helicobacter pylori infection – report of conciliation conference Maastricht IV / Florence. Vestnik Prakticheskogo Vracha. 2012;Special Issue 1:6-22 (In Russ.)].
48. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease – where next? Aliment Pharmacol Ther. 2005;22(2):79-94.
49. Evsyutina YV, Trukhmanov AS, Ivashkin VT. Family case of achalasia cardia: Case report and review of literature. World J Gastroenterol. 2014;20(4):1114-1118.
50. Boeckxstaens G, El-Serag HB, Smout AJ, Kahrilas PJ. Symptomatic reflux disease: the present, the past and the future. Gut. 2014;63(7):1185-1193.
51. Pohl D, Tutuian R. Reflux monitoring: pH-metry, Bilitec and oesophageal impedance measurements. Best Pract Res Clin Gastroenterol. 2009;23(3):299-331.
52. Mainie I, Tutuian R, Castell DO. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. J Clin Gastroenterol. 2008;42(6):676-679.
53. Rackoff A, Agrawal A, Hila A, Mainie I, Tutuian R, Castell DO. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus. 2005;18(6):370-373.
54. [Kaybysheva VO, Trukhmanov AS, Ivashkin VT. Gastroesophageal reflux disease, resistant to therapy with proton pump inhibitors. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2011;21(4):4-13 (In Russ.)].
55. Ren LH, Chen WX, Qian LJ, Li S, Gu M, Shi RH. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis. World J Gastroenterol. 2014;20(9):2412-2419.
56. Li S, Shi S, Chen F, Lin J. The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trials. Gastroenterol Res Pract. 2014;2014:307805.
57. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem. 1997;272(36):22438-22446.
58. Sarosiek I, Olyaee M, Majewski M, et al. Significant Increase of Esophageal Mucin Secretion in Patients with Reflux Esophagitis After Healing with Rabeprazole: Its Esophagoprotective Potential. Dig Dis Sci. 2009;54:2137-2142.
59. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308.
60. Jafri SM, Arora G, Triadafilopoulos G. What is left of the endoscopic antireflux devices? Curr Opin Gastroenterol. 2009;25:352.
61. Triadafilopoulos G, DiBlaise JK, Nostrant TT, et al. Long-term experience with the Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the US open label trial. Program and abstracts of Digestive Disease Week 2001; May 20-23, 2001; Atlanta, Georgia.
62. Utely DS, Kim MS, Vierra MA, et al. Augmentation of lower esophageal sphincter pressure and gastric yield pressure after radiofrequency energy delivery to the gastroesophageal junction: a porcine model. Gastrointest Endosc. 2000;52:81-86.
63. Mason RJ, Demeester TR, Schurr MO, et al. Per oral endoscopic Nissen fundoplication: the introduction of a new era. Program and abstracts of Digestive Disease Week 2001; May 20-23, 2001; Atlanta, Georgia. [ASGE Abstract #736].
64. Scarpellini E, Ang D, Pauwels A, De Santis A, Vanuytsel T, Tack J. Management of refractory typical GERD symptoms. Nat Rev Gastroenterol Hepatol. 2016;13(5):281-294.
65. Skubleny D, Switzer NJ, Dang J, et al. LINX(®) magnetic esophageal sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: a systematic review and meta-analysis. Surg Endosc. 2017;31(8):3078-3084.
doi: 10.22416/1382-4376-2017-27-4-75-95
2. Трухманов А.С. Диагностика и лечение гастроэзофагеальной рефлюксной болезни. Терапевтический архив. 2011;83(8):44-48 [Trukhmanov AS. Diagnosis and treatment of gastroesophageal reflux disease. Terapevticheskiy Arkhiv. 2011;83(8):44-48 (In Russ.)]
3. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, and the Global Consensus Group. The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. Am J Gastroenterol. 2006;101:1900-1920.
4. El-Serag HB, Ergun GA, Pandolfino J, Fitzgerald S, Tran T, Kramer JR. Obesity increases oesophageal acid exposure. Gut. 2007;56:749-755.
5. Ивашкин В.Т., Маев И.В., Трухманов А.С. Пищевод Баррета. В 2-х т. Москва: Издательство «Шико»; 2011. С. 608-624 [Ivashkin VT,
Maev IV, Trukhmanov AS. Pishchevod Barreta [Barrett’s esophagus]. Moscow: Shiko; 2011. P. 608-624 (In Russ.)].
6. Bytzer P, van Zanten SV, Mattsson H, Wernersson B. Partial symptomresponse to proton pump inhibitors in patients with nonerosive reflux disease or reflux oesophagitis – a post hoc analysis of 5796 patients. Aliment Pharmacol Ther. 2012;36:635-643.
7. Cicala M, Emerenziani S, Guarino MP, Ribolsi M. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World J Gastroenterol. 2013;19(39):6529-6535.
8. Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;23:1473-14777.
9. Johnson DA, Lauritsen K, Junghard O, Levine D. Evaluation of symptoms is an unreliable predictor of relapse of erosive esophagitis in patients receiving maintenance PPI therapy. Gastroenterology. 2003;124(4 Suppl 1):A540.
10. Fass R, Thomas S, Traxler B, Sostek M. Patient reported outcome of heartburn improvement: doubling the proton pump inhibitor (PPI) dose in patient who failed standard dose PPI vs. switching to a different PPI. Gastroenterology. 2004;146:A37.
11. Chey WD, Inadomi JM, Booher AM, Sharma VK, Fendrick AM, Howden CW. Primary-care physicians’ perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol. 2005;100(6):1237-1242.
12. Yasuda S, Ohnishi A, Ogawa T, et al. Pharmacokinetic properties of E3810 a new proton pump ingibitor, in healthy male volunteers. Int J Clin Pharmacol Ther. 1994;32;466-473.
13. Boeckxstaens GE. Alterations confined to the gastro-oesophageal junction: the relationship between low LOSP, TLOSRs, hiatus hernia and acid pocket. Best Pract Res Clin Gastroenterol. 2010;24:821-829.
14. Сhang P, Friedenberg F. Obesity and GERD. Gastroenterol Clin. 2014;43:161-173.
15. Kouklakis G, Moschos J, Kountouras J. Relationship between obesity and gastroesophageal reflux disease as recorded by 3-hour esophageal pH monitoring. Rom J Gastroenterol. 2005;14(2):117-121.
16. El-Serag HB, Ergun GA, Pandolfino J, Fitzgerald S, Tran T, Kramer JR. Obesity increases oesophageal acid exposure. Gut. 2007;56:749-755.
17. Wu JC, Lai LH, Chow DK, Wong GL, Sung JJ, Chan FK. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease. Neurogastroenterol Motil. 2011;23(2):155-160.
18. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2004;5(2):181-202.
19. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79(1):103-113.
20. Furuta T, Sugimoto M, Kodaira C, et al. CYP2C19 genotype is associated with symptomatic recurrence of GORD during maintenance therapy with low-dose lansoprazole. Eur J Clin Pharmacol. 2009;65:693-698.
21. Serrano D, Torrado S, Torrado-Santiago S, Gisbert JP. The influence of CYP2C19 Genetic polymorphism on the Pharmacokinetics/Pharmacodynamics of Proton Pump Inhibitor-Containing Helicobacter pylori treatment. Curr Drug Metab. 2012;13(9):1303-1312.
22. Евсютина Ю.В., Трухманов А.С. Новый взгляд на проблему гастроэзофагеальной рефлюксной болезни, рефрактерной к лечению ингибиторами протонной помпы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;(5):4-9 [Evsyuti-na YuV, Trukhmanov AS. A new look at the problem of gastroesophageal reflux disease, refractory to the treatment with proton pump inhibitors. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2014;(5):4-9 (In Russ.)].
23. Lee YC, Lin JT, Wang HP, et al. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. J Gastroenterol Hepatol. 2007;22(8):1286-1292.
24. Oestreich JH, Best LG, Dobesh PP. Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans. Am Heart J. 2014;167(3):413-418.
25. Isomoto H, Inoue K, Kohno S. Interleukin-8 levels in esophageal mucosa and long-term clinical outcome of patients with reflux esophagitis. Scand J Gastroenterol. 2007;42:410-411.
26. Евсютина Ю.В. Клинико-морфологические характеристики гастроэзофагеальной рефлюксной болезни, рефрактерной к лечению ингибиторами протонной помпы. Автореф. дис. … канд. мед. наук. 14.01.04 – внутренние болезни. Москва; 2015 [Evsyutina YuV. Kliniko-morfologicheskie kharakteristiki gastroezofageal’noy reflyuksnoy bolezni, refrakternoy k lecheniyu ingibitorami protonnoy pompy [Clinico-morphological characteristics of gastroesophageal reflux disease, refractory to treatment with proton pump inhibitors]. Author’s abstract. dis. ... cand. med. sciences. 14.01.04 – internal diseases. Moscow; 2015 (In Russ.)].
27. Mainie I, Tutuian R, Shay S, et al. Acid and nonacid reflux in patients with persistent symptoms despite acid suppressive therapy. A multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006 ;55:1398-1402. doi: 10.1136/gut.2005.087668
28. Kunsch S, Neesse A, Linhart T, Nell C, Gress TM, Ellenrieder V. Prospective evaluation of duodenogastroesophageal reflux in gastro-esophageal reflux disease patients refractory to proton pump inhibitor therapy. Digestion. 2012;86(4):315-322.
29. Tavakkoli A, Sayed BA, Talley NJ, Moshiree B. Acid and non-acid reflux in patients refractory to proton pump inhibitor therapy: is gastroparesis a factor? World J Gastroenterol. 2013;19(37):6193-6198.
30. Kudara N, Chiba T, Orii S, Suzuki K. Gastric emptying of patients with persistent reflux symptoms and erosive esophagitis under PPI therapy. Neurogastroenterol Motil. 2004;16:654.
31. Mirbagheri SA, Sadeghi A, Amouie M, et al. Pyloric injection of botulinum toxin for the treatment of refractory GERD accompanied with gastroparesis: a preliminary report. Dig Dis Sci. 2008;53(10):2621-2626.
32. Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology. 2009;137:588-597.
33. Calatayud S, Garcia-Zaragoza E, Hernandez C, Quintana E, Felipo V, Esplugues JV, et al. Downregulation of nNOS and synthesis of PGs associated with endotoxin-induced delay in gastric emptying. Am J Physiol Gastrointest Liver Physiol. 2002;283:G1360-G1367.
34. Ивашкин В.Т., Трухманов А.С. Эволюция представлений о роли нарушений двигательной функции пищевода в патогенезе гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2010;27(2):13-19 [Ivashkin VT, Trukhmanov AS. Evolution of ideas about the role of disorders of the motor function of the esophagus in the pathogenesis of gastroesophageal reflux disease. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2010;27(2):13-19 (In Russ.)].
35. Маев И.В., Самсонов А.А., Андреев Д.Н. Роль и место антацидов в современных алгоритмах терапии кислотозависимых заболеваний. Фарматека. 2013;(2):66-72 [Maev IV, Samsonov AA, Andreev DN. The role and place of antacids in modern algorithms for the therapy of acid-dependent diseases. Farmateka. 2013;(2):66-72 (In Russ.)].
36. Humphries TJ, Galmiche JP, Avasthy N. Rabeprazole is as effective as omeprazole in normalising esophageal acid exposure. Am J Gastroenterol. 1999;94:A2587. Abstract.
37. Pace F, Pallotta S, Casalini S, Porro GB. A review of rabeprazole in the treatment of acid-related diseases. Ther Clin Risk Manag. 2007 Jun;3(3):363-379.
38. Евсютина Ю.В., Трухманов А.С. Недостаточный ответ на терапию ингибиторами протонного насоса: причины и тактика ведения пациентов. Терапевтический архив. 2015;87(2):85-89 [Evsyutina YuV, Trukhmanov AS. Inadequate response to proton pump inhibitor therapy: causes and tactics of patient management. Terapevticheskiy Arkhiv. 2015;87(2):85-89 (In Russ.)].
39. Пасечников В.Д. Ключи к выбору оптимального ингибитора протонной помпы для терапии кислотозависимых заболеваний. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. Rossiyskiy 2004;(3):32-39 [Pasechnikov VD. Keys to choosing the optimal proton pump inhibitor for the treatment of acid-dependent diseases. Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2004;(3):32-39 (In Russ.)].
40. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003 Jun 15;17(12):1507-1514.
41. Aziz Q, Fass R, Gyawali Prakash C, et al. Esophageal disorders. Gastroenterology. 2016;150:1368-1379.
42. Шептулин А.А., Кайбышева В.О. Функциональная изжога и гиперчувствительность пищевода к рефлюксу (По материалам Римских критериев функциональных заболеваний пищевода IV пересмотра). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(2):13-18 [Sheptulin AA, Kaibysheva VO. Functional heartburn and hypersensitivity of the esophagus to reflux (Based on the Roman criteria for functional diseases of the esophagus IV revision). Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2017;27(2):13-18 (In Russ.)].
43. Mermelstein J, Mermelstein AC, Chait MM. Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. Clin Exper Gastroenterol. 2018;11:119-134.
44. Blaser MJ, Theodore E. Woodward Award: Global Warming and the Human Stomach: Microecology Follows Macroecology. Trans Am Clin Climatol Assoc. 2005;116:65-76.
45. Ahmed N, Sechi LA. Helicobacter pylori and gastroduodenal pathology: New threats of the old friend. Ann Clin Microbiol Antimicrob. 2005;4:1.
46. Nayoung Kim, Lee SW, Kim JI, et al. Effect of Helicobacter pylori Eradication on the Development of Reflux Esophagitis and Gastroesophageal Reflux Symptoms: A Nationwide Multi-Center Prospective Study. Gut Liver. 2011 Dec;5(4):437-446.
47. Диагностика и лечение инфекции Helicobacter pylori – отчет согласительной конференции Маастрихт IV/Флоренция. Вестник практического врача. 2012;Спецвыпуск 1:6-22 [Diagnosis and treatment of Helicobacter pylori infection – report of conciliation conference Maastricht IV / Florence. Vestnik Prakticheskogo Vracha. 2012;Special Issue 1:6-22 (In Russ.)].
48. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease – where next? Aliment Pharmacol Ther. 2005;22(2):79-94.
49. Evsyutina YV, Trukhmanov AS, Ivashkin VT. Family case of achalasia cardia: Case report and review of literature. World J Gastroenterol. 2014;20(4):1114-1118.
50. Boeckxstaens G, El-Serag HB, Smout AJ, Kahrilas PJ. Symptomatic reflux disease: the present, the past and the future. Gut. 2014;63(7):1185-1193.
51. Pohl D, Tutuian R. Reflux monitoring: pH-metry, Bilitec and oesophageal impedance measurements. Best Pract Res Clin Gastroenterol. 2009;23(3):299-331.
52. Mainie I, Tutuian R, Castell DO. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. J Clin Gastroenterol. 2008;42(6):676-679.
53. Rackoff A, Agrawal A, Hila A, Mainie I, Tutuian R, Castell DO. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus. 2005;18(6):370-373.
54. Кайбышева В.О., Трухманов А.С., Ивашкин В.Т. Гастроэзофагеальная рефлюксная болезнь, резистентная к терапии ингибиторами протонной помпы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2011;21(4):4-13 [Kaybysheva VO, Trukhmanov AS, Ivashkin VT. Gastroesophageal reflux disease, resistant to therapy with proton pump inhibitors. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2011;21(4):4-13 (In Russ.)].
55. Ren LH, Chen WX, Qian LJ, Li S, Gu M, Shi RH. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis. World J Gastroenterol. 2014;20(9):2412-2419.
56. Li S, Shi S, Chen F, Lin J. The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trials. Gastroenterol Res Pract. 2014;2014:307805.
57. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem. 1997;272(36):22438-22446.
58. Sarosiek I, Olyaee M, Majewski M, et al. Significant Increase of Esophageal Mucin Secretion in Patients with Reflux Esophagitis After Healing with Rabeprazole: Its Esophagoprotective Potential. Dig Dis Sci. 2009;54:2137-2142.
59. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308.
60. Jafri SM, Arora G, Triadafilopoulos G. What is left of the endoscopic antireflux devices? Curr Opin Gastroenterol. 2009;25:352.
61. Triadafilopoulos G, DiBlaise JK, Nostrant TT, et al. Long-term experience with the Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the US open label trial. Program and abstracts of Digestive Disease Week 2001; May 20-23, 2001; Atlanta, Georgia.
62. Utely DS, Kim MS, Vierra MA, et al. Augmentation of lower esophageal sphincter pressure and gastric yield pressure after radiofrequency energy delivery to the gastroesophageal junction: a porcine model. Gastrointest Endosc. 2000;52:81-86.
63. Mason RJ, Demeester TR, Schurr MO, et al. Per oral endoscopic Nissen fundoplication: the introduction of a new era. Program and abstracts of Digestive Disease Week 2001; May 20-23, 2001; Atlanta, Georgia. [ASGE Abstract #736].
64. Scarpellini E, Ang D, Pauwels A, De Santis A, Vanuytsel T, Tack J. Management of refractory typical GERD symptoms. Nat Rev Gastroenterol Hepatol. 2016;13(5):281-294.
65. Skubleny D, Switzer NJ, Dang J, et al. LINX(®) magnetic esophageal sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: a systematic review and meta-analysis. Surg Endosc. 2017;31(8):3078-3084.
________________________________________________
doi: 10.22416/1382-4376-2017-27-4-75-95
2. [Trukhmanov AS. Diagnosis and treatment of gastroesophageal reflux disease. Terapevticheskiy Arkhiv. 2011;83(8):44-48 (In Russ.)]
3. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, and the Global Consensus Group. The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. Am J Gastroenterol. 2006;101:1900-1920.
4. El-Serag HB, Ergun GA, Pandolfino J, Fitzgerald S, Tran T, Kramer JR. Obesity increases oesophageal acid exposure. Gut. 2007;56:749-755.
5. [Ivashkin VT, Maev IV, Trukhmanov AS. Pishchevod Barreta [Barrett’s esophagus]. Moscow: Shiko; 2011. P. 608-624 (In Russ.)].
6. Bytzer P, van Zanten SV, Mattsson H, Wernersson B. Partial symptomresponse to proton pump inhibitors in patients with nonerosive reflux disease or reflux oesophagitis – a post hoc analysis of 5796 patients. Aliment Pharmacol Ther. 2012;36:635-643.
7. Cicala M, Emerenziani S, Guarino MP, Ribolsi M. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World J Gastroenterol. 2013;19(39):6529-6535.
8. Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;23:1473-14777.
9. Johnson DA, Lauritsen K, Junghard O, Levine D. Evaluation of symptoms is an unreliable predictor of relapse of erosive esophagitis in patients receiving maintenance PPI therapy. Gastroenterology. 2003;124(4 Suppl 1):A540.
10. Fass R, Thomas S, Traxler B, Sostek M. Patient reported outcome of heartburn improvement: doubling the proton pump inhibitor (PPI) dose in patient who failed standard dose PPI vs. switching to a different PPI. Gastroenterology. 2004;146:A37.
11. Chey WD, Inadomi JM, Booher AM, Sharma VK, Fendrick AM, Howden CW. Primary-care physicians’ perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol. 2005;100(6):1237-1242.
12. Yasuda S, Ohnishi A, Ogawa T, et al. Pharmacokinetic properties of E3810 a new proton pump ingibitor, in healthy male volunteers. Int J Clin Pharmacol Ther. 1994;32;466-473.
13. Boeckxstaens GE. Alterations confined to the gastro-oesophageal junction: the relationship between low LOSP, TLOSRs, hiatus hernia and acid pocket. Best Pract Res Clin Gastroenterol. 2010;24:821-829.
14. Сhang P, Friedenberg F. Obesity and GERD. Gastroenterol Clin. 2014;43:161-173.
15. Kouklakis G, Moschos J, Kountouras J. Relationship between obesity and gastroesophageal reflux disease as recorded by 3-hour esophageal pH monitoring. Rom J Gastroenterol. 2005;14(2):117-121.
16. El-Serag HB, Ergun GA, Pandolfino J, Fitzgerald S, Tran T, Kramer JR. Obesity increases oesophageal acid exposure. Gut. 2007;56:749-755.
17. Wu JC, Lai LH, Chow DK, Wong GL, Sung JJ, Chan FK. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease. Neurogastroenterol Motil. 2011;23(2):155-160.
18. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2004;5(2):181-202.
19. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79(1):103-113.
20. Furuta T, Sugimoto M, Kodaira C, et al. CYP2C19 genotype is associated with symptomatic recurrence of GORD during maintenance therapy with low-dose lansoprazole. Eur J Clin Pharmacol. 2009;65:693-698.
21. Serrano D, Torrado S, Torrado-Santiago S, Gisbert JP. The influence of CYP2C19 Genetic polymorphism on the Pharmacokinetics/Pharmacodynamics of Proton Pump Inhibitor-Containing Helicobacter pylori treatment. Curr Drug Metab. 2012;13(9):1303-1312.
22. [Evsyuti-na YuV, Trukhmanov AS. A new look at the problem of gastroesophageal reflux disease, refractory to the treatment with proton pump inhibitors. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2014;(5):4-9 (In Russ.)].
23. Lee YC, Lin JT, Wang HP, et al. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. J Gastroenterol Hepatol. 2007;22(8):1286-1292.
24. Oestreich JH, Best LG, Dobesh PP. Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans. Am Heart J. 2014;167(3):413-418.
25. Isomoto H, Inoue K, Kohno S. Interleukin-8 levels in esophageal mucosa and long-term clinical outcome of patients with reflux esophagitis. Scand J Gastroenterol. 2007;42:410-411.
26.[Evsyutina YuV. Kliniko-morfologicheskie kharakteristiki gastroezofageal’noy reflyuksnoy bolezni, refrakternoy k lecheniyu ingibitorami protonnoy pompy [Clinico-morphological characteristics of gastroesophageal reflux disease, refractory to treatment with proton pump inhibitors]. Author’s abstract. dis. ... cand. med. sciences. 14.01.04 – internal diseases. Moscow; 2015 (In Russ.)].
27. Mainie I, Tutuian R, Shay S, et al. Acid and nonacid reflux in patients with persistent symptoms despite acid suppressive therapy. A multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006 ;55:1398-1402. doi: 10.1136/gut.2005.087668
28. Kunsch S, Neesse A, Linhart T, Nell C, Gress TM, Ellenrieder V. Prospective evaluation of duodenogastroesophageal reflux in gastro-esophageal reflux disease patients refractory to proton pump inhibitor therapy. Digestion. 2012;86(4):315-322.
29. Tavakkoli A, Sayed BA, Talley NJ, Moshiree B. Acid and non-acid reflux in patients refractory to proton pump inhibitor therapy: is gastroparesis a factor? World J Gastroenterol. 2013;19(37):6193-6198.
30. Kudara N, Chiba T, Orii S, Suzuki K. Gastric emptying of patients with persistent reflux symptoms and erosive esophagitis under PPI therapy. Neurogastroenterol Motil. 2004;16:654.
31. Mirbagheri SA, Sadeghi A, Amouie M, et al. Pyloric injection of botulinum toxin for the treatment of refractory GERD accompanied with gastroparesis: a preliminary report. Dig Dis Sci. 2008;53(10):2621-2626.
32. Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology. 2009;137:588-597.
33. Calatayud S, Garcia-Zaragoza E, Hernandez C, Quintana E, Felipo V, Esplugues JV, et al. Downregulation of nNOS and synthesis of PGs associated with endotoxin-induced delay in gastric emptying. Am J Physiol Gastrointest Liver Physiol. 2002;283:G1360-G1367.
34. [Ivashkin VT, Trukhmanov AS. Evolution of ideas about the role of disorders of the motor function of the esophagus in the pathogenesis of gastroesophageal reflux disease. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2010;27(2):13-19 (In Russ.)].
35.[Maev IV, Samsonov AA, Andreev DN. The role and place of antacids in modern algorithms for the therapy of acid-dependent diseases. Farmateka. 2013;(2):66-72 (In Russ.)].
36. Humphries TJ, Galmiche JP, Avasthy N. Rabeprazole is as effective as omeprazole in normalising esophageal acid exposure. Am J Gastroenterol. 1999;94:A2587. Abstract.
37. Pace F, Pallotta S, Casalini S, Porro GB. A review of rabeprazole in the treatment of acid-related diseases. Ther Clin Risk Manag. 2007 Jun;3(3):363-379.
38. [Evsyutina YuV, Trukhmanov AS. Inadequate response to proton pump inhibitor therapy: causes and tactics of patient management. Terapevticheskiy Arkhiv. 2015;87(2):85-89 (In Russ.)].
39.[Pasechnikov VD. Keys to choosing the optimal proton pump inhibitor for the treatment of acid-dependent diseases. Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2004;(3):32-39 (In Russ.)].
40. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003 Jun 15;17(12):1507-1514.
41. Aziz Q, Fass R, Gyawali Prakash C, et al. Esophageal disorders. Gastroenterology. 2016;150:1368-1379.
42. [Sheptulin AA, Kaibysheva VO. Functional heartburn and hypersensitivity of the esophagus to reflux (Based on the Roman criteria for functional diseases of the esophagus IV revision). Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2017;27(2):13-18 (In Russ.)].
43. Mermelstein J, Mermelstein AC, Chait MM. Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. Clin Exper Gastroenterol. 2018;11:119-134.
44. Blaser MJ, Theodore E. Woodward Award: Global Warming and the Human Stomach: Microecology Follows Macroecology. Trans Am Clin Climatol Assoc. 2005;116:65-76.
45. Ahmed N, Sechi LA. Helicobacter pylori and gastroduodenal pathology: New threats of the old friend. Ann Clin Microbiol Antimicrob. 2005;4:1.
46. Nayoung Kim, Lee SW, Kim JI, et al. Effect of Helicobacter pylori Eradication on the Development of Reflux Esophagitis and Gastroesophageal Reflux Symptoms: A Nationwide Multi-Center Prospective Study. Gut Liver. 2011 Dec;5(4):437-446.
47. [Diagnosis and treatment of Helicobacter pylori infection – report of conciliation conference Maastricht IV / Florence. Vestnik Prakticheskogo Vracha. 2012;Special Issue 1:6-22 (In Russ.)].
48. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease – where next? Aliment Pharmacol Ther. 2005;22(2):79-94.
49. Evsyutina YV, Trukhmanov AS, Ivashkin VT. Family case of achalasia cardia: Case report and review of literature. World J Gastroenterol. 2014;20(4):1114-1118.
50. Boeckxstaens G, El-Serag HB, Smout AJ, Kahrilas PJ. Symptomatic reflux disease: the present, the past and the future. Gut. 2014;63(7):1185-1193.
51. Pohl D, Tutuian R. Reflux monitoring: pH-metry, Bilitec and oesophageal impedance measurements. Best Pract Res Clin Gastroenterol. 2009;23(3):299-331.
52. Mainie I, Tutuian R, Castell DO. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. J Clin Gastroenterol. 2008;42(6):676-679.
53. Rackoff A, Agrawal A, Hila A, Mainie I, Tutuian R, Castell DO. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus. 2005;18(6):370-373.
54. [Kaybysheva VO, Trukhmanov AS, Ivashkin VT. Gastroesophageal reflux disease, resistant to therapy with proton pump inhibitors. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2011;21(4):4-13 (In Russ.)].
55. Ren LH, Chen WX, Qian LJ, Li S, Gu M, Shi RH. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis. World J Gastroenterol. 2014;20(9):2412-2419.
56. Li S, Shi S, Chen F, Lin J. The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trials. Gastroenterol Res Pract. 2014;2014:307805.
57. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem. 1997;272(36):22438-22446.
58. Sarosiek I, Olyaee M, Majewski M, et al. Significant Increase of Esophageal Mucin Secretion in Patients with Reflux Esophagitis After Healing with Rabeprazole: Its Esophagoprotective Potential. Dig Dis Sci. 2009;54:2137-2142.
59. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308.
60. Jafri SM, Arora G, Triadafilopoulos G. What is left of the endoscopic antireflux devices? Curr Opin Gastroenterol. 2009;25:352.
61. Triadafilopoulos G, DiBlaise JK, Nostrant TT, et al. Long-term experience with the Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the US open label trial. Program and abstracts of Digestive Disease Week 2001; May 20-23, 2001; Atlanta, Georgia.
62. Utely DS, Kim MS, Vierra MA, et al. Augmentation of lower esophageal sphincter pressure and gastric yield pressure after radiofrequency energy delivery to the gastroesophageal junction: a porcine model. Gastrointest Endosc. 2000;52:81-86.
63. Mason RJ, Demeester TR, Schurr MO, et al. Per oral endoscopic Nissen fundoplication: the introduction of a new era. Program and abstracts of Digestive Disease Week 2001; May 20-23, 2001; Atlanta, Georgia. [ASGE Abstract #736].
64. Scarpellini E, Ang D, Pauwels A, De Santis A, Vanuytsel T, Tack J. Management of refractory typical GERD symptoms. Nat Rev Gastroenterol Hepatol. 2016;13(5):281-294.
65. Skubleny D, Switzer NJ, Dang J, et al. LINX(®) magnetic esophageal sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: a systematic review and meta-analysis. Surg Endosc. 2017;31(8):3078-3084.
Авторы
В.Т. Ивашкин 1, И.В. Маев 2, А.С. Трухманов 1, Д.Е. Румянцева 1
1 ФГАОУ ВО «Первый Московский государственный университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
2 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия
1 I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia;
2 A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia
1 ФГАОУ ВО «Первый Московский государственный университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
2 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия
________________________________________________
1 I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia;
2 A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.